bispecific antibodies

1:10
Multiple myeloma treatment: let the war begin!
Gareth Morgan
2:30
AML: Targeting Wilms’ tumor 1 with WT1-TCB
Marion Subklewe
2:15
Targeting FLT3 in AML
Marion Subklewe
2:18
Redirecting T-cell cytotoxicity and proliferation
Marion Subklewe
2:45
Modulation of AMG 330-mediated T-cell proliferation and cytotoxicity
Marion Subklewe
11:42
AML treatment: what does the data say?
Adriano Venditti et al.
1:55
AML research at Dana-Farber: updates from Richard Stone
Richard Stone
1:36
Bispecific antibodies for R/R AML: ongoing clinical trials
John DiPersio
1:28
Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML
Bob Löwenberg
2:25
Analyzing AML: novel therapies in review
Farhad Ravandi
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
1:40
Antibodies for AML: updates from ASH
Marina Konopleva
2:19
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
1:21
An update on the state-of-affairs of BiTEs in the world of AML
Marion Subklewe
1:57
An update on AMG-330: can BiTEs be as successful in AML as ALL?
Marion Subklewe
1:21
Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL
Ian Flinn
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals